News & Updates

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024 byJairia Dela Cruz

In the treatment of patients with early oligoarticular psoriatic arthritis (PsA), the use of apremilast yields substantial improvements in both clinical and patient-reported outcomes, as shown in the results of the phase IV FOREMOST study.

Apremilast delivers favourable outcomes for patients with early oligoarticular PsA
01 Sep 2024
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
Tofacitinib safe, efficacious in ankylosing spondylitis regardless of baseline CRP
31 Aug 2024